| Indication |
For the local treatment of vulvovaginal candidiasis (infections caused by Candida) |
| Mechanism of action |
The exact mechanism of the antifungal action of butoconazole is unknown, however, it is presumed to function as other imidazole derivatives via inhibition of steroid synthesis. Imidazoles generally inhibit the conversion of lanosterol to ergosterol via the inhibition of the enzyme cytochrome P450 14α-demethylase, resulting in a change in fungal cell membrane lipid composition. This structural change alters cell permeability and, ultimately, results in the osmotic disruption or growth inhibition of the fungal cell. |
| Absorption |
Following vaginal administration of butoconazole nitrate vaginal cream, 2% to 3 women, 1.7% (range 1.3-2.2%) of the dose was absorbed on average. |
| Protein binding |
Not Available |
| Biotransformation |
Not Available |
| Route of elimination |
Not Available |
| Toxicity |
Oral, rat: LD50 = >1720 mg/kg. |
| Affected organisms |
- Fungi, yeast and protozoans
|